Roy A. Whitfield - 16 Sep 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4
Filing time
20 Sep 2022, 20:49:32 UTC
Previous filing
24 Sep 2021
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +10,200 +4.3% $0.000000 246,250 16 Sep 2022 Direct F1, F2
holding NKTR Common Stock 51,500 16 Sep 2022 by Whitfield Family 2020 Trust
holding NKTR Common Stock 20,000 16 Sep 2022 by Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +20,400 $0.000000 20,400 16 Sep 2022 Common Stock 20,400 $3.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2 This RSU award vests in full, one year following September 16, 2022.
F3 This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.